Evidence map›Paper›PMID 33930375›Full record

ArticleBrain research2021

Effect of hemopexin treatment on outcome after intracerebral hemorrhage in mice.

Jing Chen-Roetling, Yang Li, Yang Cao, Zhe Yan, Xiangping Lu, Raymond F Regan

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Jing Chen-RoetlingDepartment of Emergency Medicine, Thomas Jefferson University, 1025 Walnut Street, Philadelphia, PA 19107, USA.
Yang LiDepartment of Emergency Medicine, University of Maryland School of Medicine, 110 S. Paca Street, 6(th) Floor, Suite 200, Baltimore, MD 21205, USA.
Yang CaoDepartment of Emergency Medicine, Thomas Jefferson University, 1025 Walnut Street, Philadelphia, PA 19107, USA.
Zhe YanDepartment of Emergency Medicine, Thomas Jefferson University, 1025 Walnut Street, Philadelphia, PA 19107, USA.
Xiangping LuDepartment of Emergency Medicine, Thomas Jefferson University, 1025 Walnut Street, Philadelphia, PA 19107, USA.
Raymond F ReganDepartment of Emergency Medicine, Thomas Jefferson University, 1025 Walnut Street, Philadelphia, PA 19107, USA; Department of Emergency Medicine, University of Maryland School of Medicine, 110 S. Paca Street, 6(th) Floor, Suite 200, Baltimore, MD 21205, USA. Electronic address: rregan@som.umaryland.edu.
Thomas Jefferson University · US

Funding

Protective Effect of Astrocyte Heme Oxygenase-1 after Intracerebral HemorrhageR01NS095205 · NINDS · UNIVERSITY OF MARYLAND BALTIMORE · PI REGAN, RAYMOND F · 2016 to 2020
$1.7M
Effect of Hemopexin Therapy after Intracerebral HemorrhageR21NS088986 · NINDS · THOMAS JEFFERSON UNIVERSITY · PI REGAN, RAYMOND F · 2015 to 2016
$429k
NINDS NIH HHS R01 NS095205NINDS NIH HHS R21 NS088986
6 · The paper itself

Abstract

Heme release from hemoglobin may contribute to secondary injury after intracerebral hemorrhage (ICH). The primary endogenous defense against heme toxicity is hemopexin, a 57 kDa glycoprotein that is depleted in the CNS after hemorrhagic stroke. We hypothesized that systemic administration of exogenous hemopexin would reduce perihematomal injury and improve outcome after experimental ICH. Intraperitoneal treatment with purified human plasma hemopexin beginning 2 h after striatal ICH induction and repeated daily for the following two days reduced blood-brain barrier disruption and cell death at 3 days. However, it had no effect on neurological deficits at 4 or 7 days or striatal cell viability at 8 days. Continuous daily hemopexin administration had no effect on striatal heme content at 3 or 7 days, and did not attenuate neurological deficits, inflammatory cell infiltration, or perihematomal cell viability at 8 days. These results suggest that systemic hemopexin treatment reduces early injury after ICH, but this effect is not sustained, perhaps due to an imbalance between striatal tissue heme and hemopexin content at later time points. Future studies should investigate its effect when administered by methods that more efficiently target CNS delivery.

Indexed as

AnimalsBlood-Brain BarrierBrainCell DeathCerebral HemorrhageCorpus StriatumDisease Models, AnimalFemaleHemeHeme Oxygenase-1HemoglobinsHemopexinInjections, IntraperitonealMaleMiceTreatment OutcomeHemeHeme Oxygenase-1HemoglobinsHemopexinHemeHemoglobin toxicityIronStrokeStroke modelsSubararachnoid hemorrhage

Identifiers

PMID33930375
PMCPMC8206022
OpenAlexW3157405392

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.